Pfm Health Sciences, LP Prothena Corp Public LTD CO Transaction History

Pfm Health Sciences, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$32.31 - $52.32 $20.9 Million - $33.8 Million	-646,827 Reduced 77.32%	189,744 $6.9 Million
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $2.93 Million - $4.38 Million	62,025 Added 8.01%	836,571 $40.4 Million
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $4.74 Million - $5.88 Million	-100,918 Reduced 11.53%	774,546 $37.5 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $1.83 Million - $2.29 Million	35,226 Added 4.19%	875,464 $52.7 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $12.5 Million - $30 Million	495,124 Added 143.47%	840,238 $50.9 Million
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $7.84 Million - $13.8 Million	345,114 New	345,114 $9.37 Million

185

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $668M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.